PARABDRUGS

Members of the Exchange are hereby informed that the trading in equity shares of Parabolic Drugs Limited (ISIN: INE618H01016) shall be suspended w.e.f January 28, 2021 on account of Record date submitted for the purpose of Delisting pursuant to Resolution Plan approved by NCLT

PARABDRUGS: The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 17-Dec-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Change in Auditors of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)2. Date of appointment/cessation (as applicable) & term of appointmentThe response of the Company is attached.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 17-Dec-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Change in Auditors of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)<br> 2. Date of appointment/cessation (as applicable) & term of appointment<br> The response of the Company is awaited.

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 19-Oct-2018, regarding " Parabolic Drugs Limited has informed the Exchange that Intimation regarding change of IRP and appointment of RP in the matter of Corporate Insolvency Resolution Process (CIRP) Of Parabolic Drugs Limited.".On basis of above the Company is required to clarify following:1. Any other material information not involving commercial secrets<br>2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 19-Oct-2018, regarding " Parabolic Drugs Limited has informed the Exchange that Intimation regarding change of IRP and appointment of RP in the matter of Corporate Insolvency Resolution Process (CIRP) Of Parabolic Drugs Limited.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets<br> 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 14-Aug-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on August 14, 2018.".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);<br>The response of the Company is attached.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 14-Aug-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on August 14, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);<br> The response of the Company is awaited.

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2018, regarding regarding Board meeting held on May 29, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2018, regarding regarding Board meeting held on May 29, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 13-Feb-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2018.This is to inform you that the Board of Directors in its Meeting held on 13th February, 2018 and concluded at 05:10 p.m. :1. Approved the Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2017.2. This is to inform you that Mr. Ashok Kumar Jindal, Chief Financial Officer and Compliance Officer of the Company has resig

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 13-Feb-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2018.This is to inform you that the Board of Directors in its Meeting held on 13th February, 2018 and concluded at 05:10 p.m. :1. Approved the Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2017.2. This is to inform you that Mr. Ashok Kumar Jindal, Chief Financial Officer and Compliance Officer of the

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 20-Dec-2017, regarding Outcome of Board Meeting held on December 20, 2017.This is to inform you that the Board of Directors in its Meeting held on 20th December, 2017 and concluded at 03:15 p.m. : 1. This is to inform you that Ms. Ishrat Gill, Company Secretary and Compliance Officer of the Company has resigned from the service of the Company to pursue future career objectives.1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is enclo

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 20-Dec-2017, regarding Outcome of Board Meeting held on December 20, 2017.This is to inform you that the Board of Directors in its Meeting held on 20th December, 2017 and concluded at 03:15 p.m. : 1. This is to inform you that Ms. Ishrat Gill, Company Secretary and Compliance Officer of the Company has resigned from the service of the Company to pursue future career objectives.1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is await

Significant increase in price has been observed in Parabolic Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parabolic Drugs Limited has submitted their response.

Significant increase in price has been observed in Parabolic Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2017, regarding Outcome of Board Meeting held on May 29, 2017. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2017, regarding Outcome of Board Meeting held on May 29, 2017. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 10-May-2017, regarding "Parabolic Drugs Limited has informed the Exchange regarding Appointment of Mr Ashok Kumar Jindal as Chief Financial Officer of the company w.e.f. May 10, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached..

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 10-May-2017, regarding "Parabolic Drugs Limited has informed the Exchange regarding Appointment of Mr Ashok Kumar Jindal as Chief Financial Officer of the company w.e.f. May 10, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.

PARABDRUGS: The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 12-Nov-2016, regarding "Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on November 12, 2016: Inter alia.1) To take note of the resignation of Chief Financial Officer, Mr. Sandeep Sharma of the company.".On basis of above the Company is required to clarify following:1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is enclosed.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 12-Nov-2016, regarding "Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on November 12, 2016: Inter alia.1) To take note of the resignation of Chief Financial Officer, Mr. Sandeep Sharma of the company.".On basis of above the Company is required to clarify following:1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.

Significant increase in price has been observed in Parabolic Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parabolic Drugs Limited has submitted their response.

Significant increase in price has been observed in Parabolic Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

The Exchange had sought clariification from Parabolic Drugs Limited with respect to an announcement submitted to the Exchange dated August 13, 2016, regarding outcome of meeting of the Board of Directors of the Company held on August 13, 2016 wherein board has appointed Mr. Sandeep Sharma, as Chief Financial Officer of the Company.On basis of above, The Company has clarified that :"1. Mr. Sandeep Sharma was appointed as Chief Financial officer of the Company w.e.f. 13-08-2016. 2. There is no relationship between Mr. Sandeep Sharma and any of the Director of the Company. 3. Brief profile of Mr.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to an announcement submitted to the Exchange dated August 13, 2016, regarding outcome of meeting of the Board of Directors of the Company held on August 13, 2016 wherein board has appointed Mr. Sandeep Sharma, as Chief Financial Officer of the Company.On basis of above Company are required to clarify following -1. Date of appointment/cessation (as applicable) & term of appointment;2. Disclosure of relationships between directors (in case of appointment of a director).3. Brief profile (in case of appointm

Price movement : Significant price movement has been observed in Parabolic Drugs Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parabolic Drugs Limited has vide its letter inter-alia stated, "We have to submit that as on date, there exists no information as is required to be furnished to the Stock Exchange in terms of Clause 36 of the Listing Agreement."